Tag: vaccine

– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –

Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ^® in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for IXCHIQ^®. IXCHIQ^® remains indicated in the United States for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years of age and older who are at high risk of exposure to CHIKV.

SPOKANE, Wash., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Avista Corp. (NYSE: AVA) today announced financial results for the second quarter of 2025. Net income and earnings per diluted share for the second quarter and year-to-date 2025 compared to the same periods in 2024 are presented in the table below (dollars in millions, except per-share data):

Conference call and webcast scheduled for August 4, 2025, at 8:00 a.m. EDT (2:00 p.m. CEST)

COPENHAGEN, Denmark, July 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the company received a cash consideration of USD 160 million.